Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia

被引：3
|
作者：
Wei, Andrew H. [1 ,2 ]
Roboz, Gail J. [3 ,4 ]
Kantarjian, Hagop M. [5 ]
机构：
[1] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Weill Cornell Med, New York, NY USA
[4] New York Presbyterian Hosp, New York, NY USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 25期
基金：
英国医学研究理事会;
关键词：
LOW-DOSE CYTARABINE; CHEMOTHERAPY; OZOGAMICIN;
D O I：
10.1200/JCO.21.00080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
New therapies promise a brighter future for patients with AML. The pace of change has been rapid, with clinical challenges and dilemmas often arising before the availability of published answers. We believe that it is important for clinicians to share and debate these controversies to highlight current perspectives and opinions regarding new drugs not always highlighted in scientific publications. Candidly, we hope that this brief discourse will help doctors in making informed and balanced decisions on behalf of, and in collaboration with, their patients. Copyright © 2022 American Society of Clinical Oncology. All rights reserved.
引用
收藏
页码：2742 / +
页数：8
相关论文
共 50 条
  • [1] Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
    Rodriguez-Medina, Carlos
    Stuckey, Ruth
    Bilbao-Sieyro, Cristina
    Gomez-Casares, Maria Teresa
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [2] Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia
    Masayuki Kobayashi
    Takeo Yasu
    Ken Suzaki
    Nobuharu Kosugi
    [J]. Medical Oncology, 39
  • [3] Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia
    Kobayashi, Masayuki
    Yasu, Takeo
    Suzaki, Ken
    Kosugi, Nobuharu
    [J]. MEDICAL ONCOLOGY, 2022, 39 (12)
  • [4] Venetoclax in acute myeloid leukemia
    Bruzzese, Antonella
    Martino, Enrica Antonia
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Neri, Antonino
    Morabito, Fortunato
    Vigna, Ernesto
    Gentile, Massimo
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (04) : 271 - 276
  • [5] Venetoclax in Acute Myeloid Leukemia
    Mihaila, Romeo G.
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2023, 18 (01) : 11 - 28
  • [6] Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
    Brancati, Serena
    Gozzo, Lucia
    Romano, Giovanni Luca
    Vetro, Calogero
    Dulcamare, Ilaria
    Maugeri, Cinzia
    Parisi, Marina
    Longo, Laura
    Vitale, Daniela Cristina
    Di Raimondo, Francesco
    Drago, Filippo
    [J]. BLOOD, 2021, 138
  • [7] Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
    Shimony, Shai
    Stone, Richard M.
    Stahl, Maximilian
    [J]. CURRENT OPINION IN HEMATOLOGY, 2022, 29 (02) : 63 - 73
  • [8] Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine
    Siddiqui, Maria
    Maiti, Abhishek
    Daver, Naval
    Kadia, Tapan
    Rausch, Caitlin
    Alvarado, Yesid
    Ohanian, Maro
    Sasaki, Koji
    Short, Nicholas
    Takahashi, Koichi
    Yilmaz, Musa
    Ravandi, Farhad
    Kantarjian, Hagop
    DiNardo, Courtney
    Konopleva, Marina
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S303 - S304
  • [9] Venetoclax Resistance in Acute Myeloid Leukemia
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Collette, Yves
    Vey, Norbert
    [J]. CANCERS, 2024, 16 (06)
  • [10] Venetoclax in adult acute myeloid leukemia
    Hu, Mengci
    Li, Wenzhe
    Zhang, Youshan
    Liang, Caixia
    Tan, Jie
    Wang, Ya
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
12345